Commercial plans for Ryoncil™ were presented at the 2020 Biotech Showcase being held in San Francisco, CA on Jan 15, 2020.
On this day MSB share price was A$2.30-2.40
At this time, Mesoblast Chief Executive Dr. Silviu Itescu said: “We begin 2020 with great excitement as we prepare for potential FDA approval and US launch of our lead product candidate Ryoncil™ in pediatric aGVHD, a potentially life-threatening complication of an allogeneic bone marrow transplant. The continued growth in revenues from royalties on sales in Japan of the related product TEMCELL® for aGVHD by our licensee provides important insight for our own US commercial plans. Together with our strategic partners, we are also looking forward to readouts of Phase 3 trials for our blockbuster product candidates in advanced chronic heart failure and chronic low back pain due to degenerative disc disease.”
6 months later MSB share price is A$3.90
And we still have all of the news quoted above to come plus COVID ARDS trial…..
Commercial plans for Ryoncil™ were presented at the 2020 Biotech...
-
- There are more pages in this discussion • 9,330 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
88.5¢ |
Change
-0.085(8.76%) |
Mkt cap ! $1.010B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.0¢ | 88.0¢ | $9.657M | 10.58M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 140818 | 88.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 89.0¢ | 3680 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |